ECSP045114A - CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES - Google Patents

CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES

Info

Publication number
ECSP045114A
ECSP045114A EC2004005114A ECSP045114A ECSP045114A EC SP045114 A ECSP045114 A EC SP045114A EC 2004005114 A EC2004005114 A EC 2004005114A EC SP045114 A ECSP045114 A EC SP045114A EC SP045114 A ECSP045114 A EC SP045114A
Authority
EC
Ecuador
Prior art keywords
growth hormone
human growth
chemically modified
modified human
hgh
Prior art date
Application number
EC2004005114A
Other languages
Spanish (es)
Inventor
Rory F Finn
Wei Liao
Ned R Siegel
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of ECSP045114A publication Critical patent/ECSP045114A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una modificación química de la hormona de crecimiento humana (hGH) y a variantes agonistas de la misma mediante la cual se pueden cambiar las propiedades químicas y/o fisiológicas de la hGH. La hGH PEGilada puede tener una mayor duración de residencia en plasma, una menor velocidad de aclaramiento, mejor estabilidad, menos antigenicidad o una combinación de estas característicasThe present invention relates to a chemical modification of human growth hormone (hGH) and agonist variants thereof by which the chemical and / or physiological properties of hGH can be changed. PEGylated hGH may have a longer residence duration in plasma, a lower clearance rate, better stability, less antigenicity or a combination of these characteristics

EC2004005114A 2001-11-20 2004-05-20 CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES ECSP045114A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33190701P 2001-11-20 2001-11-20

Publications (1)

Publication Number Publication Date
ECSP045114A true ECSP045114A (en) 2004-07-23

Family

ID=23295870

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005114A ECSP045114A (en) 2001-11-20 2004-05-20 CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES

Country Status (25)

Country Link
EP (1) EP1453859A2 (en)
JP (2) JP2005525302A (en)
KR (2) KR20050044858A (en)
CN (1) CN1608079A (en)
AP (1) AP2004003050A0 (en)
AU (1) AU2002356990A1 (en)
BR (1) BR0214451A (en)
CA (1) CA2467731A1 (en)
CO (1) CO5580794A2 (en)
EA (2) EA008505B1 (en)
EC (1) ECSP045114A (en)
GE (1) GEP20063860B (en)
HR (1) HRP20040448A2 (en)
HU (1) HUP0500997A2 (en)
IL (1) IL162031A0 (en)
IS (1) IS7268A (en)
MA (1) MA27544A1 (en)
MX (1) MXPA04004809A (en)
NO (1) NO20042182L (en)
OA (1) OA13063A (en)
PL (1) PL374354A1 (en)
RS (1) RS53104A (en)
TN (1) TNSN04090A1 (en)
WO (1) WO2003044056A2 (en)
ZA (1) ZA200403907B (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
WO2003049699A2 (en) * 2001-12-11 2003-06-19 Sun Bio, Inc. Novel monofunctional polyethylene glycol aldehydes
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
DK1476181T3 (en) * 2002-01-18 2016-05-23 Biogen Ma Inc POLYALKYLENE POLYMER COMPOUNDS AND USE THEREOF
MXPA05002620A (en) 2002-09-09 2005-05-05 Nektar Therapeutics Al Corp Water-soluble polymer alkanals.
EP1591467A1 (en) * 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
EP1673464A2 (en) * 2003-10-10 2006-06-28 Novo Nordisk A/S Conjugation of peptides
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
EP2368579A1 (en) * 2004-01-21 2011-09-28 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
JP2008511610A (en) * 2004-08-31 2008-04-17 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Glycerol-branched polyethylene glycol-human growth hormone conjugates, methods for their production and use
MX2007007590A (en) 2004-12-22 2007-12-10 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides.
US8080391B2 (en) * 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
EP2284191A3 (en) * 2004-12-22 2011-07-20 Ambrx, Inc. Process for the preparation of hGH
JP2008531482A (en) 2005-02-10 2008-08-14 ノボ ノルディスク アクティーゼルスカブ Growth hormone with PEGylated C-terminus
BRPI0609079A2 (en) 2005-04-18 2010-11-16 Novo Nordisk As peptide, pharmaceutical composition, method for the treatment of cancer, use of a peptide nucleic acid construct, vector, host, and, antibody
WO2007025988A2 (en) 2005-08-30 2007-03-08 Novo Nordisk Health Care Ag Liquid formulations of pegylated growth hormone
HRP20110404T1 (en) * 2005-11-08 2011-08-31 Ambrx Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
ES2529065T3 (en) * 2005-12-14 2015-02-16 Ambrx, Inc. Compositions they contain, procedures that involve and uses of unnatural amino acids and polypeptides
US9175061B2 (en) * 2006-07-07 2015-11-03 Novo Nordisk Health Care Ag Protein conjugates and methods for their preparation
CN101108895B (en) * 2006-07-19 2011-10-26 北京键凯科技有限公司 Polyglycol ethanal derivant and combo of medicament and the same
CN101553501A (en) 2006-10-26 2009-10-07 诺沃-诺迪斯克有限公司 IL-21 variants
CL2008002399A1 (en) * 2007-08-16 2009-01-02 Pharmaessentia Corp Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c.
BRPI0822530B1 (en) * 2008-04-03 2022-03-22 Biosteed Gene Expression Tech. Co., Ltd Method of preparing a polyethylene glycolated human growth hormone (peg-modified), peg-modified human growth hormone of lower apparent molecular weight and its use, preparation of peg-modified human growth hormone of lower apparent molecular weight and its method of preparation and composition
DK2279007T3 (en) 2008-04-29 2016-08-22 Ascendis Pharma Growth Disorders Div As Pegylated recombinant relations of human growth hormone
KR101104574B1 (en) * 2008-05-14 2012-01-11 성균관대학교산학협력단 Human Growth Hormone Chemically Modified with Polyethylene Glycol, Method of Preparation and Use thereof
CN102131844B (en) * 2008-07-31 2016-03-02 药华医药股份有限公司 Peptide-polymer conjugates
MX2011000847A (en) 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Conjugated proteins with prolonged in vivo efficacy.
RU2409669C9 (en) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Method for immobilising biologically active substance (bas) on carrier (versions) and bas-carrier conjugate produced by such methods
EP2331139B1 (en) * 2008-09-11 2019-04-17 Nektar Therapeutics Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method
MX2011007736A (en) 2009-01-22 2011-09-06 Novo Nordisk Healthcare Ag Stable growth hormone compounds.
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
DK2512450T3 (en) 2009-12-15 2018-04-23 Ascendis Pharma Endocrinology Div A/S Dry growth hormone composition transiently bound to a polymer carrier
CN118767117A (en) 2010-01-22 2024-10-15 诺沃—诺迪斯克保健股份有限公司 Growth hormone with prolonged effect in vivo
BR112012018162A2 (en) 2010-01-22 2017-10-03 Novo Nordisk Healthcare Ag STABLE GROWTH HORMONE COMPOUNDS
CA2798518A1 (en) * 2010-05-17 2011-11-24 Cebix, Inc. Pegylated c-peptide
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
EA019967B1 (en) * 2011-12-21 2014-07-30 Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") Polyethyleneglycol covalent conjugate with human growth hormone
CN105120887A (en) 2013-04-05 2015-12-02 诺和诺德保健股份有限公司 Growth hormone compound formulation
US11559567B2 (en) 2014-11-06 2023-01-24 Pharmaessentia Corporation Dosage regimen for pegylated interferon
US10799563B2 (en) 2014-11-18 2020-10-13 Ascendis Pharma Endocrinology Division Polymeric hGH prodrugs
PL3220892T3 (en) 2014-11-21 2022-01-31 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms
KR20170125839A (en) * 2015-03-11 2017-11-15 넥타르 테라퓨틱스 Conjugates of an il-7 moiety and an polymer
KR102152437B1 (en) * 2015-09-18 2020-09-07 고쿠리츠 다이가쿠 호징 미야자키 다이가쿠 Long acting adrenomedulin derivatives
SG11202108735QA (en) 2019-03-04 2021-09-29 Ascendis Pharma Endocrinology Div A/S Long-acting growth hormone dosage forms with superior efficacy to daily somatropin
CN114539384B (en) * 2020-11-19 2024-09-06 江苏众红生物工程创药研究院有限公司 Pegylated long-acting growth hormone, preparation method and medical application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
ES2113354T3 (en) * 1990-05-04 1998-05-01 American Cyanamid Co STABILIZATION OF SOMATOTROPINS AND OTHER PROTEINS BY MODIFICATION OF CYSTEINE WASTE.
JPH06506217A (en) * 1991-03-18 1994-07-14 エンゾン，インコーポレーテッド Hydrazine-containing conjugates of polypeptides or glycopolypeptides and polymers
AU2147192A (en) * 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP3628333B2 (en) * 1995-09-21 2005-03-09 ジェネンテック インコーポレーテッド Human growth hormone mutant
IL133974A0 (en) * 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
ATE526401T1 (en) * 1999-01-14 2011-10-15 Bolder Biotechnology Inc METHOD FOR PRODUCING PROTEINS WITH FREE CYSTEINE RESIDUE
IL144361A0 (en) * 1999-01-29 2002-05-23 Hoffmann La Roche Gcsf conjugates
WO2001076639A2 (en) * 2000-04-06 2001-10-18 Pharmacia Corporation Chemically-modified myelopoietin conjugates
WO2002055532A2 (en) * 2001-01-11 2002-07-18 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds

Also Published As

Publication number Publication date
MA27544A1 (en) 2005-10-03
HRP20040448A2 (en) 2006-02-28
JP2005525302A (en) 2005-08-25
NO20042182L (en) 2004-08-11
KR20070072924A (en) 2007-07-06
GEP20063860B (en) 2006-06-26
EP1453859A2 (en) 2004-09-08
WO2003044056A2 (en) 2003-05-30
RS53104A (en) 2006-10-27
TNSN04090A1 (en) 2006-06-01
PL374354A1 (en) 2005-10-17
KR20050044858A (en) 2005-05-13
EA200700431A1 (en) 2008-02-28
ZA200403907B (en) 2007-12-27
CA2467731A1 (en) 2003-05-30
IL162031A0 (en) 2005-11-20
MXPA04004809A (en) 2004-08-11
EA200400565A1 (en) 2005-06-30
CN1608079A (en) 2005-04-20
WO2003044056A3 (en) 2003-08-21
JP2006321808A (en) 2006-11-30
HUP0500997A2 (en) 2007-11-28
CO5580794A2 (en) 2005-11-30
AP2004003050A0 (en) 2004-06-30
BR0214451A (en) 2006-05-30
EA008505B1 (en) 2007-06-29
IS7268A (en) 2004-05-17
AU2002356990A1 (en) 2003-06-10
OA13063A (en) 2006-11-10

Similar Documents

Publication Publication Date Title
ECSP045114A (en) CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES
EP1196444B8 (en) Exendin-4 conjugates and their medical use
WO2004009774A3 (en) Protein conjugates with a water-soluble biocompatible, biogradable polymer
PL374178A1 (en) Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
DE602004017252D1 (en) Body care compositions Compositions containing structured conditioner premix
EA200301222A1 (en) PULMONARY INTRODUCTION OF CHEMICALLY MODIFIED INSULIN
IL173299A0 (en) Methods of treating or preventing autoimmune diseases with 2,4- pyrimidinediamine compounds
NO20053556D0 (en) Polymer conjugates of interferon-beta with enhanced biological potency.
AU2002329990A1 (en) Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
ATE552031T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING NON-ACYLATED GHRELIN FOR THE TREATMENT OF INSULIN RESISTANCE
EA200400399A1 (en) METHODS OF TREATMENT OF PULMONARY DISEASES
PL1522312T3 (en) Biologically stable liquid composition of FVIII, of vWF or of FVIII/vWF complex of human origin.
PL367450A1 (en) Cyclic ketones as blocking agents
BRPI0412803A (en) unglycosylated human alpha-fetoprotein, production methods and uses thereof
WO2004039326A3 (en) Propofol with cysteine
DE502004010644D1 (en) FLAVORED MEDICAMENT FORMULATIONS WITH IMPROVED PHARMACEUTICAL PROPERTIES
IL164195A0 (en) Parenteral, intravenous, and oral administration of oxazolidinones for treating diabetic foot infections
DE60030654D1 (en) Lasofoxifen-containing compositions
WO2004085471A3 (en) Glp-2 derivatives
TR200601608T1 (en) Long-acting compositions comprising an avermectin combination.
ZA200205880B (en) Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith.
AU2002327440A1 (en) Treatment of type i diabetes
AP2248A (en) Treatment of HI-virus infections with oxidised blood proteins.
DE60238681D1 (en) IMPLANTABLE MINIATURE CONNECTORS
CR7346A (en) CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES